Evidence map›Paper›PMID 24747160›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2014

An overview of clinical and commercial impact of drug delivery systems.

Aaron C Anselmo, Samir Mitragotri

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Cyclodextrin-based therapeutics delivery systems: A review of current clinical trials.Current research in pharmacology and drug discovery · 2025
    Review
  19. Review
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aaron C AnselmoDepartment of Chemical Engineering, Center for Bioengineering, University of California, Santa Barbara 93106, USA.
Samir MitragotriDepartment of Chemical Engineering, Center for Bioengineering, University of California, Santa Barbara 93106, USA. Electronic address: samir@engineering.ucsb.edu.

Funding

Orally bioactive exenatie and insulin for type II diabetesR01DK097379 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI MITRAGOTRI, SAMIR S · 2013 to 2016
$1.3M
NIDDK NIH HHS R01 DK097379NIDDK NIH HHS R01DK097379
6 · The paper itself

Abstract

Drug delivery systems are widely researched and developed to improve the delivery of pharmaceutical compounds and molecules. The last few decades have seen a marked growth of the field fueled by increased number of researchers, research funding, venture capital and the number of start-ups. Collectively, the growth has led to novel systems that make use of micro/nano-particles, transdermal patches, inhalers, drug reservoir implants and antibody-drug conjugates. While the increased research activity is clearly an indication of proliferation of the field, clinical and commercial translation of early-stage research ideas is critically important for future growth and interest in the field. Here, we will highlight some of the examples of novel drug delivery systems that have undergone such translation. Specifically, we will discuss the developments, advantages, limitations and lessons learned from: (i) microparticle-based depot formulations, (ii) nanoparticle-based cancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery, (vi) implants and (vii) antibody-drug conjugates. These systems have impacted treatment of many prevalent diseases including diabetes, cancer and cardiovascular diseases, among others. At the same time, these systems are integral and enabling components of products that collectively generate annual revenues exceeding US $100 billion. These examples provide strong evidence of the clinical and commercial impact of drug delivery systems.

Indexed as

Drug Delivery SystemsAdministration, CutaneousAntibiotics, AntineoplasticDoxorubicinForecastingHumansNanoparticlesPolyethylene GlycolsAntibiotics, AntineoplasticDoxorubicinliposomal doxorubicinPolyethylene GlycolsClinical translationDrug deliveryHistoricalLab to clinicPerspectivePharmaceutics

Identifiers

PMID24747160
PMCPMC4142089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.